Table I.
Activity of SCH 727965 against cell lines in the PPTP in vitro panel
| Cell Line | Histology | Rel IC50 (nM) | Abs IC50 (nM) | T/C% at 1.0 μM | Ymin (T/C%) | Relative I/O |
|---|---|---|---|---|---|---|
| RD | Rhabdomyosarcoma | 8.2 | 8.6 | 1.1 | 1.1 | −79.7% |
| Rh41 | Rhabdomyosarcoma | 10.5 | 10.8 | 12.6 | 7.8 | −65.0% |
| Rh18 | Rhabdomyosarcoma | 10.5 | 11.2 | 19.1 | 17.7 | −60.4% |
| Rh30 | Rhabdomyosarcoma | 9.0 | 9.3 | 4.4 | 4.3 | −74.2% |
| BT-12 | Rhabdoid | 8.5 | 8.7 | 0.1 | 0.1 | −98.4% |
| CHLA-266 | Rhabdoid | 7.3 | 7.5 | 1.6 | 1.5 | −94.2% |
| TC-71 | Ewing sarcoma | 3.9 | 3.9 | 0.0 | 0.0 | −99.4% |
| CHLA-9 | Ewing sarcoma | 8.0 | 8.1 | 0.2 | 0.2 | −95.3% |
| CHLA-10 | Ewing sarcoma | 6.3 | 6.8 | 0.2 | 0.2 | −97.1% |
| CHLA-258 | Ewing sarcoma | 9.9 | 10.1 | 2.6 | 0.8 | −97.9% |
| GBM2 | Glioblastoma | 6.5 | 7.1 | 3.3 | 2.7 | −72.4% |
| NB-1643 | Neuroblastoma | 3.3 | 3.4 | 13.3 | 6.9 | −67.4% |
| NB-EBc1 | Neuroblastoma | 7.0 | 7.2 | 10.0 | 0.4 | −98.2% |
| CHLA-90 | Neuroblastoma | 7.5 | 7.6 | 0.3 | 0.1 | −99.5% |
| CHLA-136 | Neuroblastoma | 9.8 | 9.7 | 16.1 | 4.2 | −85.3% |
| NALM-6 | ALL | 4.6 | 4.7 | 0.1 | 0.1 | −95.1% |
| COG-LL-317 | ALL | 6.5 | 6.4 | 0.0 | 0.0 | −100.0% |
| RS4;11 | ALL | 5.1 | 5.1 | 1.9 | 0.4 | −97.2% |
| MOLT-4 | ALL | 9.3 | 9.1 | 0.1 | 0.0 | −99.7% |
| CCRF-CEM | ALL | 5.6 | 5.7 | 0.5 | 0.3 | −94.6% |
| Kasumi-1 | AML | 4.5 | 4.6 | 0.0 | 0.0 | −99.9% |
| Karpas-299 | ALCL | 3.9 | 3.9 | 0.0 | 0.0 | −100.0% |
| Ramos-RA1 | NHL | 7.9 | 8.1 | 0.0 | 0.0 | −100.0% |
| Median | 7.3 | 7.5 | 0.52 | 0.34 | −97.1% | |
| Minimum | 3.3 | 3.4 | 0.00 | 0.00 | −100.0% | |
| Maximum | 10.5 | 11.2 | 19.11 | 17.68 | −60.4% |
percentage difference between the Ymin value and the estimated starting cell number and either the control cell number (for agents with Ymin > starting cell number) or 0 (for agents with Ymin < estimated starting cell number).